other drugs
no. | product name | specification | us dmf | eu dmf | cep | jp dmf | cde status |
---|---|---|---|---|---|---|---|
1 | acarbose 阿卡波糖 |
usp, ep, cp, jp, in house | ● | ● | ● | a | |
usp, ep, cp, jp, in house | the document has been approved | the document has been approved | the document has been approved | apis that have been approved for use in finished dosage in china | |||
2 | ademetionine 1, 4-butanedisulfonate 1, 4-丁二磺酸腺苷蛋氨酸 |
ybh | ● | a | |||
ybh | apis that have been approved for use in finished dosage in china | ||||||
3 | apixaban 阿哌沙班 |
in house | ● | a | |||
in house | the document has been approved | apis that have been approved for use in finished dosage in china | |||||
4 | apremilast 阿普司特 |
in house | |||||
in house | |||||||
5 | aripiprazole 阿立哌唑 |
usp, ep, in house | ● | a | |||
usp, ep, in house | the document has been approved | apis that have been approved for use in finished dosage in china | |||||
6 | dabigatran etexilate mesylate 甲磺酸达比加群酯 |
in house | ● | ||||
in house | the document has been approved | ||||||
7 | eltrombopag olamine 艾曲波帕乙醇胺 |
in house | |||||
in house | |||||||
8 | glutathione 谷胱甘肽 |
ybh | a | ||||
ybh | apis that have been approved for use in finished dosage in china | ||||||
9 | loxapine succinate 丁二酸洛沙平 |
in house | a | ||||
in house | apis that have been approved for use in finished dosage in china | ||||||
10 | lurasidone hcl 盐酸鲁拉西酮 |
in house | ● | a | |||
in house | the document has been approved | apis that have been approved for use in finished dosage in china | |||||
11 | mycophenolate mofetil 吗替麦考酚酯 |
usp, ep, cp | ● | ● | a | ||
usp, ep, cp | the document has been approved | the document has been approved | apis that have been approved for use in finished dosage in china | ||||
12 | olanzapine 奥氮平 |
usp | ● | ||||
usp | the document has been approved | ||||||
13 | orlistat 奥利司他 |
usp, in house | ● | a | |||
usp, in house | apis that have been approved for use in finished dosage in china | ||||||
14 | oseltamivir phosphate 磷酸奥司他韦 |
cp、usp、ep、in house | |||||
cp、usp、ep、in house | |||||||
15 | parecoxib sodium 帕瑞昔布钠 |
in house | a | ||||
in house | apis that have been approved for use in finished dosage in china | ||||||
16 | sirolimus 西罗莫司 |
in house | ● | ● | a | ||
in house | the document has been approved | apis that have been approved for use in finished dosage in china | |||||
17 | solifenacin succinate 琥珀酸索利那新 |
in house | a | ||||
in house | apis that have been approved for use in finished dosage in china | ||||||
18 | tofacitinib citrate 枸橼酸托法替布 |
in house | a | ||||
in house | apis that have been approved for use in finished dosage in china | ||||||
19 | tacrolimus 他克莫司 |
usp, ep, ip | ● | ● | a | ||
usp, ep, ip | the document has been approved | the document has been approved | apis that have been approved for use in finished dosage in china | ||||
20 | ticagrelor 替格瑞洛 |
in house | ● | ||||
in house | the document has been approved | ||||||
21 | glucosamine sulfate sodium chloride 硫酸氨基葡萄糖氯化钠复盐 |
ybh | a | ||||
ybh | apis that have been approved for use in finished dosage in china |